Are You An Anchor Study Expert?

15 Questions

SettingsSettingsSettings
Are You An Anchor Study Expert? - Quiz

15 questions about the key elements of the ANCHOR Study


Questions and Answers
  • 1. 
    Who was the primary investigator for the year 2 results of the ANCHOR study?
    • A. 

      Sanjoy T. Khan

    • B. 

      David M. Brown

    • C. 

      Lester B. Pearson

    • D. 

      James S. Sykes

  • 2. 
    What was the objective of the ANCHOR study?
    • A. 

      Compare Lucentis with Avastin and Eylea

    • B. 

      Compare Ranibizumab and Aflibercept in the treatment of predominantly classic CNV (Choroidal Neovascularization)

    • C. 

      Compare 0.3 and 0.5 mg doses of Ranibizumab in treating predominantly Occult CNV 

    • D. 

      Compare Ranibizumab with Verteporfin Photodynamic Therapy (PDT) in treating predominantly classic CNV

  • 3. 
    What was the design of the ANCHOR study?
    • A. 

      Single country, triple masked, randomized study

    • B. 

      Multi-Center, international, randomized, double masked, active treatment, controlled clinical trial.

    • C. 

      North American, double masked, 12 month, randomized study

    • D. 

      Global, single masked, retroactive clinical study

  • 4. 
    What were the main outcome measures of the ANCHOR study?
    • A. 

      Number of injections over 24 months; change in Visual Acuity (VA) from baseline

    • B. 

      % losing < 10 letters from baseline; % gaining 10 letters or more in VA; FA-assessed lesion characteristics 

    • C. 

      % losing < 15 letters from baseline; % gaining 15 letters or more in VA; FA-assessed lesion characteristics 

    • D. 

      % losing 5 or more letters; % gaining more than 10 letters; number of injections

  • 5. 
    What were the 3 groups that took part in the ANCHOR study?
    • A. 

      Verteporfin PDT plus monthly sham intraocular injection; Sham Verteporfin PDT plus monthly 0.3 mg Ranibizumab intraocular injection ; Sham Verteporfin PDT plus monthly 0.5 mg Ranibizumab intraocular injection 

    • B. 

      Sham Verteporfin PDT plus monthly 0.3 mg Ranibizumab intraocular injection ; Sham Verteporfin PDT plus monthly 0.5 mg Ranibizumab intraocular injection 

    • C. 

      Monthly Avastin intraocular injection; Sham Verteporfin PDT plus monthly 0.3 mg Ranibizumab intraocular injection ; Sham Verteporfin PDT plus monthly 0.5 mg Ranibizumab intraocular injection

    • D. 

      Verteporfin PDT plus monthly sham intraocular injection; Sham Verteporfin PDT plus monthly 0.3 mg Ranibizumab intraocular injection

  • 6. 
    How many patients started the ANCHOR Study and what % finished?
    • A. 

      198; 91%

    • B. 

      243; 74%

    • C. 

      423; 77%

    • D. 

      514; 82%

  • 7. 
    What was the overall result in change in VA from baseline for the 3 groups in the ANCHOR Study at the end of 24 months?
    • A. 

      0.3 mg Ranibizumab gained 10.7 letters on average; 0.5 mg Ranibizumab gained 8.1 on average; PDT LOST 9.8 letters on average 1

    • B. 

      0.3 mg Ranibizumab gained 8.1 letters on average; 0.5 mg Ranibizumab gained 10.7 on average; PDT gained 9.8 letters on average

    • C. 

      0.3 mg Ranibizumab gained 10.1 letters on average; 0.5 mg Ranibizumab gained 10.7 on average; PDT gained 10.8 letters on average

    • D. 

      0.3 mg Ranibizumab gained 8.1 letters on average; 0.5 mg Ranibizumab gained 10.7 on average; PDT LOST 9.8 letters on average

  • 8. 
    Prior to the approval of verteporfin in 2001, what was the expected outcome for patients with classic Choroidal Neovascularization (CNV)?
    • A. 

      Deterioration of all vision but not likely to be classified as legally blind

    • B. 

      Temporary loss of the majority of non central vision

    • C. 

      Permanent loss of the majority of central vision within 3 to 9 months of diagnosis

    • D. 

      Loss of Drivers Licence 

  • 9. 
    What was the pivotal finding of the ANCHOR study?
    • A. 

      A cardiovascular therapy could be used effectively in retina patients.

    • B. 

      Off label use of Avastin for retina therapy was almost as effective as Ranibizumab.

    • C. 

      This proved that anti-VEGf therapy was effective in preventing cataracts.

    • D. 

      This was the 1st demonstration that a therapy could not only prevent further VA loss but also provide clinically meaningful improvement in VA in a substantial proportion of patients with predominately classic CNV.

  • 10. 
    What was the primary efficacy endpoint of the ANCHOR study? (Primary end point was at 12 months. All other efficacy endpoints were secondary including those at 24 months).
    • A. 

      Proportion of patients who at 12 months lost fewer than 15 letters (~3 lines) from baseline.

    • B. 

      Proportion of patients who at 12 months gained more than 15 letters (~3 lines) from baseline.

    • C. 

      Proportion of patients who at 12 months lost fewer than 15 letters (~3 lines) or gained more than 15 (~3 lines) letters from baseline.

    • D. 

      Proportion of patients who had more than 100 microns of thinning of the retina from baseline at 12 months.

  • 11. 
    What other study, along with the ANCHOR Study, let to the United States Food & Drug Administration approval of Ranibizumab for treatment of all angiographic subtypes of CNV secondary to AMD in June 2006?
    • A. 

      TREND

    • B. 

      TREX

    • C. 

      MARINA

    • D. 

      FIREFOX

  • 12. 
    How many sites were used in the ANCHOR study?
    • A. 

      44

    • B. 

      72

    • C. 

      112

    • D. 

      83

  • 13. 
    How many subjects had both eyes in the study?
    • A. 

      0

    • B. 

      22

    • C. 

      14

    • D. 

      54

  • 14. 
    What was the letter/gain loss of the Ranibizumab groups at Day 7?
    • A. 

      Ranibizumab 0.5mg: 4.6 letters; Ranibizumab 0.3 mg 5.2 letters

    • B. 

      Ranibizumab 0.5mg: 4.6 letters; Ranibizumab 0.3 mg 2.1 letters

    • C. 

      Ranibizumab 0.5mg: 4.6 letters; Ranibizumab 0.3 mg 11.1 letters

    • D. 

      Ranibizumab 0.5mg: 4.6 letters; Ranibizumab 0.3 mg 2.9 letters

  • 15. 
    What was the rate of presumed endophtalmitis in the study eye per injection?
    • A. 

      1.4%

    • B. 

      2.2%

    • C. 

      0.05%

    • D. 

      0.0003%

Back to Top Back to top
×

Wait!
Here's an interesting quiz for you.

We have other quizzes matching your interest.